Table 5 Main and secondary outcomes for medicine groups at six week follow up
Variable | Mebeverine | Methylcellulose | Placebo | Significance |
|---|---|---|---|---|
IBS-SSS total mean (n = 123) | 183.3 (156.9-209.7) | 174.0 (149.7-198.4) | 210.6 (185.6-235.5) | p = 0.106 |
IBS-QOL score (n = 123) | 69.5 (65.7-73.4) | 69.4 (65.8-73.0) | 69.7 (66.0-73.3) | p = 0.994 |
HADS score for anxiety (n = 114) | 8.7 (7.7-9.7) | 9.0 (8.1-9.9) | 9.2 (8.3-10.1) | p = 0.743 |
HADS score for depression (n = 114) (%) |  |  |  | p = 0.590 |
Normal (0–7) | 29 (30.9) | 36 (38.3) | 29 (30.9) |  |
Mild (8–10) | 3 (16.7) | 5 (27.8) | 10 (55.6) |  |
Moderate or Severe (11–21) | 2 (40.0) | 0 (0) | 3 (60.0) |  |
Enablement score (n = 113) |  |  |  | p = 0.563 |
0 | 6 (19.4) | 14 (35.9) | 12 (27.9) | Â |
1-2 | 5 (16.1) | 6 (15.4) | 5 (11.6) | Â |
3-5 | 9 (29.0) | 11 (28.2) | 15 (34.9) | Â |
6-12 | 11 (35.5) | 8 (20.5) | 11 (25.6) | Â |